Expert NetworkExpert InterviewCLDX

Slingshot members are talking to an expert! The topic is:

Discussing the 52 week results of the Barzolvolimab Phase 2 study in CSU (Chronic Spontaneous Urticaria) at EADV 2024

Executed on:Oct 9, 2024 12:00 PM EDT
Call Duration:30 minutes

Expert Profile

ExpertBlinded Expert
Institution: University of Rochester
  • Professor of Dermatology, Professor of Medicine (AIR) and Pathology & Laboratory Medicine at University of Rochester Medical Center.
  • Manages 500 patients with atopic dermatitis (60% Pediatric) and 30 patients per month with chronic urticaria.
  • Research was instrumental in the development of dupilumab (Dupixent); Lead author of a 2014 NEJM paper that set the stage for the FDA approval of Dupixent.

Interview Goal

Discuss 52 week results of barzolvolimab and how it stacks up against Xolair and other agents in CSU

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.